GlassScriptPhysician profile
Danny R Bartel
NPI 1679535843
$46,471.39
in general payments reported to CMS, 2019-2025
74 companies · $5,119 in 2025
The $5,119 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,928 · 2020: $19K · 2021: $4,465 · 2022: $4,776 · 2023: $5,365 · 2024: $4,048 · 2025: $5,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,124.51 |
| Education | $407.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,093.07 | 2019-2020 | |
| Emd Serono, INC. | $7,483.45 | 2019-2022 | |
| Biogen, INC. | $2,728.94 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Supernus Pharmaceuticals, INC. | $2,523.74 | 2019-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $2,045.60 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $1,684.70 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,406.04 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,229.83 | 2020-2025 | Ubrelvy, Duopa, Qulipta |
| Ucb, INC. | $1,139.91 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $1,085.81 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $1,015.00 | 2019-2025 | Soliris, Ultomiris |
| Celgene Corporation | $1,000.24 | 2021-2025 | Zeposia |
| Genzyme Corporation | $998.83 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $794.69 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $745.22 | 2020-2025 | Acthar |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $720.79 | 2019-2025 | |
| Sk Life Science, INC. | $718.48 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $715.85 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Abbott Laboratories | $694.33 | 2019-2023 | Infinity |
| Argenx US, INC. | $659.57 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ani Pharmaceuticals, INC. | $586.45 | 2022-2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $582.51 | 2020-2025 | Wakix |
| Amgen INC. | $565.01 | 2019-2025 | Uplizna |
| Kyowa Kirin, INC. | $544.29 | 2020-2023 | Nourianz |
| Horizon Therapeutics Plc | $474.08 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $433.32 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Csl Behring | $360.48 | 2019-2025 | Hizentra |
| Sumitomo Pharma America, INC. | $334.50 | 2023-2024 | Aptiom |
| Eisai INC. | $312.70 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $296.71 | 2020-2022 | |
| Acorda Therapeutics, INC | $287.28 | 2019-2023 | Ampyra, Inbrija |
| Lundbeck LLC | $267.17 | 2020-2025 | Vyepti, Rexulti |
| Grifols USA, LLC | $256.21 | 2019-2025 | Gamunex-C |
| Revance Therapeutics, INC. | $255.69 | 2024 | Daxxify |
| Mdd US Operations, LLC | $222.62 | 2019-2025 | Apokyn, Gocovri |
| Axsome Therapeutics, INC. | $216.66 | 2024-2025 | Sunosi, Symbravo |
| Tanabe Pharma America, INC. | $213.22 | 2019-2025 | Radicava |
| Upsher-Smith Laboratories LLC | $184.27 | 2019-2023 | |
| Corium, LLC | $161.25 | 2022-2025 | Adlarity, Azstarys |
| Vanda Pharmaceuticals INC. | $160.71 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $159.91 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $146.94 | 2022-2025 | Xeomin, Inbrija |
| Almatica Pharma LLC | $143.70 | 2021-2022 | |
| Lilly USA, LLC | $136.22 | 2019-2025 | Emgality, Reyvow, Zepbound |
| Neuropace, INC. | $135.36 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $130.59 | 2022 | |
| Si-Bone, INC. | $124.30 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $123.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.41 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $103.67 | 2019-2025 | |
| Ge Healthcare | $103.16 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $94.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.69 | 2019-2020 | |
| Radius Health, INC. | $81.22 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $62.59 | 2022-2023 | Keveyis |
| Sentynl Therapeutics, INC. | $60.04 | 2019 | |
| Octapharma USA, INC. | $45.71 | 2022-2023 | Panzyga, Octagam Immune Globulin (Human) |
| Neurelis, INC. | $45.40 | 2024-2025 | Valtoco |
| Adamas Pharmaceuticals, INC. | $43.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.22 | 2025 | Wainua |
| Amneal Pharmaceuticals LLC | $34.25 | 2019-2025 | Crexont |
| Boston Scientific Corporation | $31.86 | 2021 | |
| C2n Diagnostics, LLC | $21.89 | 2025 | Precivityad2 |
| Tersera Therapeutics LLC | $21.48 | 2025 | Quzyttir |
| Janssen Pharmaceuticals, INC | $19.22 | 2023 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $18.88 | 2024 | Nuedexta |
| Strongbridge US INC. | $17.39 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.20 | 2020 | |
| Springworks Therapeutics, INC. | $15.70 | 2025 | Gomekli |
| Catalyst Pharmaceuticals, INC. | $15.40 | 2020 | |
| Janssen Biotech, INC. | $15.35 | 2025 | |
| Impel Pharmaceuticals INC. | $11.88 | 2022 | |
| Collegium Pharmaceutical, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Bartel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.